Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Autoimmunity Highlights
Erschienen in: Autoimmunity Highlights 2/2014

01.09.2014 | Review Article

Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside

verfasst von: D. Squatrito, G. Emmi, E. Silvestri, L. Ciucciarelli, M. M. D’Elios, D. Prisco, L. Emmi

Erschienen in: Autoimmunity Highlights | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Systemic lupus erythematosus (SLE) is considered an autoimmune disease with multiorgan involvement. Many advances have been made during the last decade regarding inflammatory pathways, genetic and epigenetic alterations, adaptive and innate immune system mechanisms specifically involved in SLE pathogenesis. Apoptosis has been proposed as an important player in SLE pathogenesis more than a decade ago. However, only recently new key apoptotic pathways have been investigated and the link between apoptotic debris containing autoantigens, innate immunity and ongoing inflammation has been further elucidated. Better understanding of cellular mechanisms and involved cytokines contributed to the development of new biological drugs specifically addressed for SLE therapy.
Literatur
1.
Rahman A, Isemberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939PubMed
2.
Jimenez S, Cervera R, Font J, Ingelmo M (2003) The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 25:3–12PubMed
3.
Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:277–287
4.
Pons-Estel GJ, Alarcón GS, Sconfield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39(4):257–268PubMedPubMedCentral
5.
Cervera R, Khamashta MA, Font J, Sebastiani GD (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175
6.
Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL (2010) Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 10:3–7PubMed
7.
Janko C, Schorn C, Grossmayer GE, Frey B, Herrmann M, Gaipl US, Munoz LE (2008) Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev 8(1):9–12PubMed
8.
Shrivastav M, Niewold TB (2013) Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 7(4):319
9.
Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA (2010) Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol 6:461–479PubMedPubMedCentral
10.
Crow MK (2008) Collaboration, genetic associations and lupus erythematosus. N Eng J Med 358:956–961
11.
Bowness P, Davies KA, Norsworthy PJ, Athanassiou P, Taylor-Wiedeman J, Borysiewicz LK, Meyer PA, Walport MJ (1994) Hereditary C1q deficiency and systemic lupus erythematosus. QJM 87(8):455–464PubMed
12.
Monticielo OA, Mucenic T, Machado Xavier R, Tavares Brenol JC, Bogo Chies JA (2008) The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol 27:413–419PubMed
13.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100(5):2610–2615PubMedPubMedCentral
14.
Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG et al (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 50(12):3958–3967PubMed
15.
Rönnblom L, Alm GV, Eloranta ML (2011) The type I interferon system in the development of lupus. Semin Immunol 23:113–121PubMed
16.
Deng Y, Tsao BP (2010) Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 6(12):683–92.10
17.
Zhao S, Long H, Qiaanjin L (2010) Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers and therapeutic potentials. Clin Rev Allergy Immunol 39:3–9
18.
Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, Xiong SD (2007) DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46:1796–1803
19.
Ballestar E, Esteller M, Richardson BC (2006) The epigenetic face of systemic lupus erythematosus. J Immunol 176:7143–7147PubMed
20.
Rigby RJ, Vinuesa CG (2008) Silencing SLE: the power and promise of small noncoding RNAs. Curr Opin Rheumatol 20:526–531PubMed
21.
Stagakis E, Bertsias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, Iliopoulos D, Boumpas DT (2011) Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: mir-21 regulates aberrant T-cells response trough the regulation of PDCD4 expression. Ann Rheum Dis 70:1496–1506PubMed
22.
Weckerle CE, Niewold TB (201) The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol 40:42–49
23.
González DA, Díaz BB, Rodríguez Pérez Mdel C, Hernández AG, Chico BN, De León AC (2010) Sex hormones and autoimmunity. Immunol Lett 133:6–13PubMed
24.
Kassi E, Moutsatsou P (2010) Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2010:317–452
25.
Wang J, Nuite M, McAlindon TE (2010) Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus 19(6):734–740PubMedPubMedCentral
26.
Shoenfeld Y, Tincani A, Gershwin ME (2012) Sex gender and autoimmunity. J Autoimmun 38(2–3):J71–J73PubMed
27.
Hudson CA, Cao L, Kasten-Jolly J, Kirkwood JN, Lawrence DA (2003) Susceptibility of lupus-prone NZM mouse strains to lead exacerbation of systemic lupus erythematosus symptoms. J Toxicol Environ Health A 66(10):895–918PubMed
28.
Hughes GC, Clark EA (2007) Regulation of dendritic cells by female sex steroids: relevance to immunity and autoimmunity. Autoimmunity 40(6):470–481PubMed
29.
Tayel SS, Helmy AA, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI (2013) Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Arch Virol 158(8):1755–1764PubMed
30.
Shelly S, Boaz M, Orbach H (2012) Prolactin and autoimmunity. Autoimmun Rev 11(6–7):A465–A467PubMed
31.
Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, Atzeni F, Zampieri S, Ghirardello A (2008) Infections as trigger and complications of systemic lupus erythematosus. Autoimmun Rev 8:24–28PubMed
32.
Zandman-Goddard G, Schoenfeld Y (2005) Infections and SLE. Autoimmunity 38:473–485PubMed
33.
Poole BD, Scofield RH, Harley JB, James JA (2006) Epstein–Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39:63–70PubMed
34.
James J, Harley JB, Scofield RH (2006) Role of Epstein–Barr virus in systemic lupus erythematosus. Curr Opin Rheumatol 18:462–467PubMed
35.
Werth VP (2007) Cutaneous lupus: insight into pathogenesis and disease classification. Bull NYU Hosp Jt Dis 65:200–204PubMed
36.
Kuhn A, Wenzel J, Weyd H (2014) Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol. (Epub ahead of print)
37.
Chang C, Gershwin ME (2010) Drugs and autoimmunity—a contemporary review and mechanistic approach. J Autoimmun 34(3):J266–J275PubMed
38.
Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6:280–289PubMed
39.
Ravichandran KS, Lorenz U (2007) Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 7:964–974PubMed
40.
Mevorach D, Trahtemberg U, Krispin A, Attalah M, Zazoun J, Tabib A, Grau A, Verbovetski-Reiner I (2010) What do we mean when we write “senescence,” “apoptosis,” “necrosis,” or “clearance of dying cells”? Ann N Y Acad Sci 1209:1–9
41.
Poon IK, Lucas CD, Rossi AG, Ravichandran KS (2014) Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol 14(3):166–180PubMedPubMedCentral
42.
Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209PubMedPubMedCentral
43.
Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR (2012) Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 32:395–402PubMed
44.
Hurst J, Von Landenberg P (2008) Toll-like receptors and autoimmunity. Autoimmun Rev 7:204–208PubMed
45.
Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6:823–835PubMed
46.
Theofilopoulos AN (2012) TLRs and IFNs: critical pieces of the autoimmunity puzzle. J Clin Invest 122(10):3464–3466
47.
48.
Kontaki E, Boumpas DT (2010) Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J Autoimmun 35:206–211PubMed
49.
Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB (2010) The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 12:207PubMedPubMedCentral
50.
Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16:47–57PubMedPubMedCentral
51.
Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52(5):1491–1503PubMed
52.
Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, Lauwerys BR (2007) Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 56(5):1579–1588
53.
Liu Z, Davidson A (2013) IFNα inducible models of murine SLE. Front Immunol 2(4):306
54.
Koss MN, Stohl W, Kovats S, Jacob CO (2009) Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 183(9):6021–6029PubMedPubMedCentral
55.
Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S (2005) IFN-α induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J. Immunol 174:2499–2506
56.
Fairhurst AM et al (2008) Systemic IFN-α drives kidney nephritis in B6.SLE123 mice. Eur J Immunol 38:1948–1960PubMedPubMedCentral
57.
Wilson LE, Widman D, Dikman SH, Gorevic PD (2002) Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 32(3):163–173PubMed
58.
Rönnblom LE, Alm GV, Öberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumor. J Intern Med 227:207–210PubMed
59.
Hargraves MM, Richmond H, Morton R (1948) Presentation of two bone marrow elements; the tart cell and the LE cell. Proc Staff Meet Mayo Clin 23:25–28PubMed
60.
Branzk N, Papayannopoulos V (2013) Molecular mechanisms regulating NETosis in infection and disease. Semin Immunopathol 35(4):513–530PubMedPubMedCentral
61.
Knight JS, Kaplan MJ (2012) Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis. Curr Opin Rheumatol 24:441–450PubMed
62.
Garcia-Romo GS et al (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3:73ra20
63.
Hakkim A, Furnrohr BG, Amann K et al (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 107:9813–9818PubMedPubMedCentral
64.
Scheinecker C, Bonelli M, Smolen JS (2010) Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun 35:269–275PubMed
65.
Peng SL (2009) Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev 8:179–183PubMed
66.
Truchetet ME, Mossalayi MD, Boniface K (2013) IL-17 in the rheumatologist’s line of sight. Biomed Res Int 2013:295132PubMedPubMedCentral
67.
Nalbandian A, Crispín JC, Tsokos GC (2009) Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 157(2):209–215PubMedPubMedCentral
68.
Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, Lan JL (2012) The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 21(13):1385–1396PubMed
69.
Ohl K, Tenbrock K (2011) Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011, Art id 432595
70.
Savino MT, Ulivieri C, Emmi G, Prisco D, De Falco G, Ortensi B, Beccastrini E, Emmi L, Pelicci G, D’Elios MM, Baldari CT (2013) The Shc family protein adaptor, Rai, acts as a negative regulator of Th17 and Th1 cell development. J Leukoc Biol 93(4):549–559PubMed
71.
Valencia X, Yarboro C, Illei G, Lipsky PE (2007) Deficient CD4+ CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178:2579–2588PubMed
72.
Bonelli M et al (2008) Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 20:861–868PubMed
73.
Yu A, Zhu L, Altman NH, Malek TR (2009) A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30:204–217PubMedPubMedCentral
74.
Wan S, Xia C, Morel L (2007) IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+ CD25+ T cell regulatory functions. J. Immunol 178:271–279PubMed
75.
Chen X, Oppenheim JJ (2014) Th17 cells and Tregs: unlikely allies. J Leukoc Biol
76.
Gerli R, Nocentini G, Alunno A, Bocci EB, Bianchini R, Bistoni O, Riccardi C (2009) Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 8:426–430PubMed
77.
Kuhn A, Beissert S, Krammer PH (2009) CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res 301:71–81PubMed
78.
Jenks SA, Sanz I (2009) Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 8(3):209–213PubMedPubMedCentral
79.
Grammer AC, Lipsky PE (2003) B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5:S22–S27PubMedPubMedCentral
80.
Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC (1996) B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 98(11):2549–2557PubMedPubMedCentral
81.
Liu K, Mohan C (2009) Altered B-cell signaling in lupus. Autoimmun Rev 8:214–218PubMed
82.
Lopes-Carvalho T, Kearney JF (2005) Marginal zone B cell physiology and disease. Curr Dir Autoimmun 8:91–123PubMed
83.
Martinez-Gamboa L, Mei H, Loddenkemper C, Ballmer B, Hansen A, Lipsky PE, Emmerich F, Radbruch A, Salama A, Dörner T (2009) Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol 130(2):199–212PubMed
84.
Sang A, Zheng YY, Morel L (2013) Contributions of B cells to lupus pathogenesis. Mol Immunol [Epub ahead of print]
85.
Wither JE, Roy V, Brennan LA (2000) Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB × NZW)F(1) mice. Clin Immunol 94(1):51–63PubMed
86.
Wang JH, Wu Q, Yang P, Li H, Li J, Mountz JD, Hsu HC (2011) Type I interferon-dependent CD86(high) marginal zone precursor B cells are potent T cell costimulators in mice. Arthritis Rheum 63(4):1054–1064PubMedPubMedCentral
87.
Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, Steiniger B, Staudt LM, Casanova JL, Reynaud CA, Weill JC (2004) Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104(12):3647–3654PubMedPubMedCentral
88.
Anolik JH et al (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56:3044–3056PubMed
89.
Goode I, Xu H, Ildstad ST (2014) Regulatory B cells: the new “it” cell. Transplant Proc 46(1):3–8
90.
Iwata Y, Matsushita T, Horikawa M et al (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117:530–541PubMedPubMedCentral
91.
Matsushita T, Horikawa M, Iwata Y, Tedder TF (2010) Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 185:2240–2252PubMedPubMedCentral
92.
Carter NA, Rosser EC, Mauri C (2012) Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 14(1):R32PubMedPubMedCentral
93.
Yang X, Yang J, Chu Y, Xue Y, Xuan D, Zheng S, Zou H (2014) T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus. PLoS One 9(2):e88441PubMedPubMedCentral
94.
95.
Manjarrez-Orduño N, Quách TD, Sanz I (2009) B cells and immunological tolerance. J Invest Dermatol 129(2):278–288PubMed
96.
97.
Ding H, Wang L, Wu X, Yan J, He Y, Ni B et al (2010) Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice. J Cell Mol Med 14:1717–1725PubMedPubMedCentral
98.
Chu VT, Enghard P, Schürer S, Steinhauser G, Rudolph B, Riemekasten G (2009) Berek C Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60:2083–2093PubMed
99.
Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F (2013) The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24(3):203–215PubMed
100.
Yildirim-Toruner C, Diamond B (2011) Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127:303–312
101.
Vincent FB, Morand EF, Schneider P, Mackay F (2014) The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10(6):365–373
102.
Dörner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5(8):433–441PubMed
103.
Mok MY (2010) The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 13:3–11PubMed
104.
Silverman GJ (2006) Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 54(8):2356–2367PubMed
105.
García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, Zamudio-Huerta L, López-Colombo A, Cervera R (2009) Use of rituximab in patients with systemic lupus erythematosus. Autoimmun Rev 8:343–348PubMed
106.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of Rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222–233PubMedPubMedCentral
107.
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215–1226PubMed
108.
Isenberg D (2012) Rituximab-it was the best of times, it was the worst of times. Autoimmun Rev 11(11):790–791PubMed
109.
Reddy V, Jayne D, Close D, Isenberg D (2013) B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 15(Suppl 1):S2PubMedPubMedCentral
110.
Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73(1):183–190PubMedPubMedCentral
111.
Stohl W, Scholz JL, Cancro MP (2011) Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol 23:305–310PubMedPubMedCentral
112.
Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61(9):1168–1178PubMedPubMedCentral
113.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731PubMed
114.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930PubMed
115.
Ginzler EM et al (2014) Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 41(2):300–309
116.
Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14:R33PubMedPubMedCentral
117.
Wang X, Huang W, Mihara M, Sinha J, Davidson A (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168:2046–2053PubMed
118.
Merrill JT (2013) Co-stimulatory molecules as targets for treatment of lupus. Clin Immunol 148(3):369–375PubMed
119.
Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(12):3251–3258PubMed
120.
Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48(3):719–727PubMed
121.
Sidiropoulos PI, Boumpas DT (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13(5):391–397PubMed
122.
Wang X, Huang W, Mihara M, Sinha J, Davidson A (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168(4):2046–2053PubMed
123.
Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(10):3077–3087PubMed
124.
Mok CC (2012) Abatacept for systemic lupus erythematosus: the outlook. Expert Opin Biol Ther 12(12):1559–1561PubMed
125.
Van Vollenhoven RF, Parodis I, Levitsky A (2013) Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol 27(3):341–349PubMed
126.
Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN, Feldmann M et al (1993) Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupuserythematosus. Arthritis Rheum 36(8):1111–1120PubMed
127.
Postal M, Appenzeller S (2011) The role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 56(3):537–543PubMed
128.
Aringer M, Smolen JS (2012) Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 11(5):321–325PubMed
129.
Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50(10):3161–3169PubMed
130.
Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847–861PubMed
131.
Soforo E, Baumgartner M, Francis L, Allam F, Phillips PE, Perl A (2010) Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 37(1):204–205PubMed
132.
Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147(1):117–123PubMed
133.
Woodrick RS, Ruderman EM (2011) Interleukin 6 inhibition—RA and beyond. Bull NYU Hosp Jt Dis 69(3):225–229PubMed
134.
Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62(2):542–552PubMedPubMedCentral
135.
Kamata Y, Minota S (2012) Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep 21:2012
136.
Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW Jr, Gordon R, Hsu B (2013) Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 65(10):2661–2671PubMed
137.
Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60(6):1785–1796PubMed
138.
McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666–3676PubMed
139.
Lichtman AI, Helfgott SM, Kriegel MA (2012) Emerging therapies for systemic lupus erythematosus—focus on targeting interferon-alpha. Clin Immunol 143:210–221PubMedPubMedCentral
140.
Lauwerys BR, Ducreux J, Houssiau FA (2013) Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford) 53(8):1369–1376
Metadaten
Titel
Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside
verfasst von
D. Squatrito
G. Emmi
E. Silvestri
L. Ciucciarelli
M. M. D’Elios
D. Prisco
L. Emmi
Publikationsdatum
01.09.2014
Verlag
Springer International Publishing
Erschienen in
Autoimmunity Highlights / Ausgabe 2/2014
Print ISSN: 2038-0305
Elektronische ISSN: 2038-3274
DOI
https://doi.org/10.1007/s13317-014-0058-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise